Clinical Trial Update: Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial studying tucatinib in combination with Doxil for HER2-positive metastatic breast cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Tucatinib (tucatinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING